Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Capricor Therapeutics (CAPR) Receivables: 2015-2024

Historic Receivables for Capricor Therapeutics (CAPR) over the last 3 years, with Dec 2024 value amounting to $20.4 million.

  • Capricor Therapeutics' Receivables fell 0.02% to $20.4 million in Q4 2024 from the same period last year, while for Dec 2024 it was $45.9 million, marking a year-over-year increase of 66.34%. This contributed to the annual value of $20.4 million for FY2024, which is 0.02% down from last year.
  • Latest data reveals that Capricor Therapeutics reported Receivables of $20.4 million as of FY2024, which was down 0.02% from $20.4 million recorded in FY2023.
  • Over the past 5 years, Capricor Therapeutics' Receivables peaked at $20.4 million during FY2023, and registered a low of $20.4 million during FY2024.
  • Its 2-year average for Receivables is $20.4 million, with a median of $20.4 million in 2023.
  • Data for Capricor Therapeutics' Receivables shows a maximum YoY decreased of 0.02% (in 2024) over the last 5 years.
  • Over the past 2 years, Capricor Therapeutics' Receivables (Yearly) stood at $20.4 million in 2023, then dropped by 0.02% to $20.4 million in 2024.